Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia / Hochhaus, A; O'Brien, Sg; Guilhot, F; Druker, Bj; Branford, S; Foroni, L; Goldman, Jm; Müller, Mc; Radich, Jp; Rudoltz, M; Mone, M; Gathmann, I; Hughes, Tp; Larson, Ra; Hughes T, IRIS I. n. v. e. s. t. i. g. a. t. o. r. s.; Taylor, K; Durant, S; Schwarer, A; Joske, D; Seymour, J; Grigg, A; Ma, D; Arthur, C; Bradstock, K; Joshua, D; Agis, H; Verhoef, G; Louwagie, A; Martiat, P; Bosly, A; Shepherd, J; Shistok, C; Lipton, J; Forrest, D; Walker, I; Roy, Dc; Rubinger, M; Bence Bruckler, I; Stewart, D; Kovacs, M; Turner, Ar; Nielsen, J; Birgens, H; Bjerrum, O; Rousselot, P; Reiffers, J; Facon, T; Harousseau, Jl; Tulliez, M; Guerci, A; Blaise, D; Maloisel, F; Michallet, M; Fischer, T; Hochhaus, A; Andreesen, R; Nerl, C; Freund, M; Gattermann, N; Ehninger, G; Niederwieser, D; Ottmann, Og; Peschel, C; Ho, Ad; Neubauer, A; le Coutre, P; Aulitzky, W; Saglio, G; Baccarani, M; Fanin, R; Rosti, G; Mandelli, F; Lazzarino, M; Morra, E; Carella, A; Petrini, M; Nobile, F; Liso, V; Ferrara, F; Rizzoli, Vittorio; Fiortoni, G; Martinelli, G; Cornelissen, J; Ossenkoppele, G; Browett, P; Gedde Dahl, T; Tangen, Jm; Dahl, I; Cervantes, F; Odrizoala, J; Hernandez Boulda, Jc; Steegmann, Jl; Canizo, C; Diaz, J; Grenena, A; Fernandez, M; Simonsson, B; Stenke, L; Paul, C; Bjoreman, M; Malm, C; Wadenvik, H; Nilsson, Pg; Turesson, I; Gratwohl, A; Hess, U; Solenthaler, M; Goldman, Jm; Clark, Re; Green, A; Holyoake, T; Lucas, G; Smith, G; Milligan, D; Rule, S; Burnett, A; Kantarjian, H; Silver, R; Stone, R; Powell, B; Gabrilove, J; Moroose, R; Wetzler, M; Bearden, J; Cataland, S; Rabinowitz, I; Meisenberg, B; Thompson, K; Graziano, S; Emanuel, P; Gross, H; Cobb, P; Bhatia, R; Dakhil, S; Irwin, Ad; Issell, B; Pavletic, S; Kuebler, P; Layhe, E; Butra, P; Glass, J; Moore, J; Grant, B; Neill, H; Herzig, R; Burris, H; Petersen, B; Kalaycio, M; Stirewalt, D; Samlowski, W; Berman, E; Limentani, S; Seay, T; Shea, T; Akard, L; Smith, G; Becker, P; Devine, S; Hart, R; Veith, R; Wade, J; Brunvad, M; Kalman, L; Strickland, D; Shurafa, M; Bashey, A; Shadduck, R; Safah, H; Rubenstein, M; Collins, R; Keller, A; Tallman, M; Pecora, A; Agha, M; Homes, H; Guidice, R; Druker, Bj; Guilhot, F; Larson, Ra; O'Brien, S; Rowe, J; Schiffer, Ca; Buyse, M; Baccarani, M; Cervantes, F; Cornelissen, J; Fischer, T; Hochhaus, A; Hughes, T; Lechner, K; Nielsen, Jl; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, Jm; Talpaz, M; Taylor, K; Verhoef, G; Santini, V.. - In: LEUKEMIA. - ISSN 0887-6924. - (2009).
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Hochhaus A; O'Brien SG; Guilhot F; Druker BJ; Branford S; Foroni L; Goldman JM; Müller MC; Radich JP; Rudoltz M; Mone M; Gathmann I; Hughes TP; Larson RA; IRIS I.n.v.e.s.t.i.g.a.t.o.r.s. Hughes T; Taylor K; Durant S; Schwarer A; Joske D; Seymour J; Grigg A; Ma D; Arthur C; Bradstock K; Joshua D; Agis H; Verhoef G; Louwagie A; Martiat P; Bosly A; Shepherd J; Shistok C; Lipton J; Forrest D; Walker I; Roy DC; Rubinger M; Bence Bruckler I; Stewart D; Kovacs M; Turner AR; Nielsen J; Birgens H; Bjerrum O; Rousselot P; Reiffers J; Facon T; Harousseau JL; Tulliez M; Guerci A; Blaise D; Maloisel F; Michallet M; Fischer T; Hochhaus A; Andreesen R; Nerl C; Freund M; Gattermann N; Ehninger G; Niederwieser D; Ottmann OG; Peschel C; Ho AD; Neubauer A; le Coutre P; Aulitzky W; Saglio G; Baccarani M; Fanin R; Rosti G; Mandelli F; Lazzarino M; Morra E; Carella A; Petrini M; Nobile F; Liso V; Ferrara F; RIZZOLI, Vittorio ;Fiortoni G; Martinelli G; Cornelissen J; Ossenkoppele G; Browett P; Gedde Dahl T; Tangen JM; Dahl I; Cervantes F; Odrizoala J; Hernandez Boulda JC; Steegmann JL; Canizo C; Diaz J; Grenena A; Fernandez M; Simonsson B; Stenke L; Paul C; Bjoreman M; Malm C; Wadenvik H; Nilsson PG; Turesson I; Gratwohl A; Hess U; Solenthaler M; Goldman JM; Clark RE; Green A; Holyoake T; Lucas G; Smith G; Milligan D; Rule S; Burnett A; Kantarjian H; Silver R; Stone R; Powell B; Gabrilove J; Moroose R; Wetzler M; Bearden J; Cataland S; Rabinowitz I; Meisenberg B; Thompson K; Graziano S; Emanuel P; Gross H; Cobb P; Bhatia R; Dakhil S; Irwin AD; Issell B; Pavletic S; Kuebler P; Layhe E; Butra P; Glass J; Moore J; Grant B; Neill H; Herzig R; Burris H; Petersen B; Kalaycio M; Stirewalt D; Samlowski W; Berman E; Limentani S; Seay T; Shea T; Akard L; Smith G; Becker P; Devine S; Hart R; Veith R; Wade J; Brunvad M; Kalman L; Strickland D; Shurafa M; Bashey A; Shadduck R; Safah H; Rubenstein M; Collins R; Keller A; Tallman M; Pecora A; Agha M; Homes H; Guidice R; Druker BJ; Guilhot F; Larson RA; O'Brien S; Rowe J; Schiffer CA; Buyse M; Baccarani M; Cervantes F; Cornelissen J; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Reiffers J; Rousselot P; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Talpaz M; Taylor K; Verhoef G; Santini V.
2009-01-01
Citazione
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia / Hochhaus, A; O'Brien, Sg; Guilhot, F; Druker, Bj; Branford, S; Foroni, L; Goldman, Jm; Müller, Mc; Radich, Jp; Rudoltz, M; Mone, M; Gathmann, I; Hughes, Tp; Larson, Ra; Hughes T, IRIS I. n. v. e. s. t. i. g. a. t. o. r. s.; Taylor, K; Durant, S; Schwarer, A; Joske, D; Seymour, J; Grigg, A; Ma, D; Arthur, C; Bradstock, K; Joshua, D; Agis, H; Verhoef, G; Louwagie, A; Martiat, P; Bosly, A; Shepherd, J; Shistok, C; Lipton, J; Forrest, D; Walker, I; Roy, Dc; Rubinger, M; Bence Bruckler, I; Stewart, D; Kovacs, M; Turner, Ar; Nielsen, J; Birgens, H; Bjerrum, O; Rousselot, P; Reiffers, J; Facon, T; Harousseau, Jl; Tulliez, M; Guerci, A; Blaise, D; Maloisel, F; Michallet, M; Fischer, T; Hochhaus, A; Andreesen, R; Nerl, C; Freund, M; Gattermann, N; Ehninger, G; Niederwieser, D; Ottmann, Og; Peschel, C; Ho, Ad; Neubauer, A; le Coutre, P; Aulitzky, W; Saglio, G; Baccarani, M; Fanin, R; Rosti, G; Mandelli, F; Lazzarino, M; Morra, E; Carella, A; Petrini, M; Nobile, F; Liso, V; Ferrara, F; Rizzoli, Vittorio; Fiortoni, G; Martinelli, G; Cornelissen, J; Ossenkoppele, G; Browett, P; Gedde Dahl, T; Tangen, Jm; Dahl, I; Cervantes, F; Odrizoala, J; Hernandez Boulda, Jc; Steegmann, Jl; Canizo, C; Diaz, J; Grenena, A; Fernandez, M; Simonsson, B; Stenke, L; Paul, C; Bjoreman, M; Malm, C; Wadenvik, H; Nilsson, Pg; Turesson, I; Gratwohl, A; Hess, U; Solenthaler, M; Goldman, Jm; Clark, Re; Green, A; Holyoake, T; Lucas, G; Smith, G; Milligan, D; Rule, S; Burnett, A; Kantarjian, H; Silver, R; Stone, R; Powell, B; Gabrilove, J; Moroose, R; Wetzler, M; Bearden, J; Cataland, S; Rabinowitz, I; Meisenberg, B; Thompson, K; Graziano, S; Emanuel, P; Gross, H; Cobb, P; Bhatia, R; Dakhil, S; Irwin, Ad; Issell, B; Pavletic, S; Kuebler, P; Layhe, E; Butra, P; Glass, J; Moore, J; Grant, B; Neill, H; Herzig, R; Burris, H; Petersen, B; Kalaycio, M; Stirewalt, D; Samlowski, W; Berman, E; Limentani, S; Seay, T; Shea, T; Akard, L; Smith, G; Becker, P; Devine, S; Hart, R; Veith, R; Wade, J; Brunvad, M; Kalman, L; Strickland, D; Shurafa, M; Bashey, A; Shadduck, R; Safah, H; Rubenstein, M; Collins, R; Keller, A; Tallman, M; Pecora, A; Agha, M; Homes, H; Guidice, R; Druker, Bj; Guilhot, F; Larson, Ra; O'Brien, S; Rowe, J; Schiffer, Ca; Buyse, M; Baccarani, M; Cervantes, F; Cornelissen, J; Fischer, T; Hochhaus, A; Hughes, T; Lechner, K; Nielsen, Jl; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, Jm; Talpaz, M; Taylor, K; Verhoef, G; Santini, V.. - In: LEUKEMIA. - ISSN 0887-6924. - (2009).
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Sei sicuro che questo prodotto debba essere cancellato?
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione.
